@uconnresearch here is more on the trouble of dilution and venture capital: https://techcrunch.com/2016/09/16/venture-capital-is-a-hell-of-a-drug/ If you can bootstrap (granted harder if not impossible in pharma and material science) do it. Go indie, don't give up control